Home/Pipeline/Neurodegeneration Pipeline

Neurodegeneration Pipeline

Neurodegenerative Diseases

PreclinicalActive

Key Facts

Indication

Neurodegenerative Diseases

Phase

Preclinical

Status

Active

Company

Origenis

About Origenis

Origenis is a private, preclinical-stage biotech firm utilizing an integrated AI and wet-lab platform to pioneer small molecule therapeutics for underserved diseases. Its core technology, featuring components like Cippix®, MolMind®, and MOREsytem®, enables the design and optimization of novel compounds with a focus on tissue-specific delivery, particularly to the brain and eye. The company has established early validation through historical and potentially ongoing collaborations with entities like Vivoryon and Alcon, and is advancing internal pipelines in neurodegeneration, brain cancer, and ophthalmology.

View full company profile

Therapeutic Areas

Neurodegeneration Oncology Ophthalmology

Other Neurodegenerative Diseases Drugs

Drug	Company	Phase	Status
Undisclosed	Modulo Bio	Discovery	Active
PBI-01207	Phoenix Biotechnology	Pre-clinical	Active
Therapeutic Target Discovery Platform	ValtedSeq	Discovery	Active
Undisclosed Neurology Program(s)	Base4	Preclinical	Active
Platform Application for Neurodegenerative Diseases	ALTUCELL	Pre-clinical/Research	Active
OGG1 Activator Program	Luciole Pharmaceuticals	Pre-clinical	Active
Lysosome Biology Program	Talisman Therapeutics	Preclinical	Active
Microglial Health Program	Talisman Therapeutics	Preclinical	Active
HSF1 Activator Program	Sisu Pharma	Pre-clinical	Active
Platform-derived candidates	VRG Therapeutics	Pre-clinical	Active
Neurodegenerative Biomarkers R&D	Firalis	Development	Active
Enhanced Brain Delivery (EBD™) Platform	Acumen Pharmaceuticals	Preclinical	Research Stage